A Study of the Value of Trio Genome Sequencing in the Etiological Evaluation of Early-Onset and/or Atypical Psychiatric Disorders Without Intellectual Disability or Congenital Anomalies (PSYGEN)
According to the World Health Organization, one in eight people worldwide has a mental disorder, defined as a significant impairment in thinking, emotional regulation, or behavior. These disorders are classified according to the DSM-5. These psychiatric disorders may be atypical in terms of their age of onset, course of the illness, unusual response to treatment, or classification (significant impact but classified as a "disorder not otherwise specified" by the DSM-5). These disorders can occur sporadically or run in families.
In France, there are no genetic testing recommendations for these patients. A CGH-array analysis may be ordered as part of patient care, as may testing for Fragile X syndrome, depending on the clinical context.
The main hypothesis is that atypical psychiatric disorders result from multifactorial inheritance, involving a combination of common genetic variations and environmental factors. Pangenomic association studies and twin studies have already demonstrated heritability in these psychiatric disorders. It has now been shown that some neurodevelopmental disorders (NDDs) and psychiatric disorders-such as autism spectrum disorders or schizophrenia, for which similar hypotheses were proposed in the past-may result from monogenic inheritance. Furthermore, preliminary indications now allow for the prescription of genome sequencing on the platforms of the France Genomic Medicine Plan 2025.
To date, no study has evaluated the role of high-throughput sequencing in an etiological approach to atypical, non-syndromic psychiatric disorders. Through this study, we aim to assess whether genome sequencing (GS) could be relevant for atypical, non-syndromic psychiatric disorders, which would be the case if it leads to an etiological diagnosis in at least 12% of cases.
The establishment of the GénoPsy network (Centers of Excellence for Behavioral Disorders in Developmental Disorders) creates an environment that is highly conducive to the development of this project.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Caroline RACINE
- 電話番号：+33 03.80.29.53.13
- メール：caroline.racine@chu-dijon.fr
研究場所
-
-
-
Dijon、フランス、21000
- CHU Dijon Bourgogne
-
コンタクト：
- Caroline RACINE
- 電話番号：+33 03.80.29.53.13
- メール：caroline.racine@chu-dijon.fr
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Index case with one or more psychiatric disorders confirmed by a psychiatrist and/or child psychiatrist, whose evaluations may be supplemented as needed as part of their care, and who meets at least ONE of the following criteria for atypicality:
- Early age of onset
- Unusual course of the disorder (polymorphic/fluctuating)
- Treatment resistance
- Disorder classified as "unspecified" by the DSM-5 with significant functional impact
- Index case aged 3 to 50 years, inclusive
- Consent signed by the biological parents and by the "index case, if of legal age"
- Index case and their parents enrolled in or eligible for a social security program
- Sample collection possible from the index case and their two known biological parents
Exclusion Criteria:
- Genetic testing previously performed (CGH array, targeted gene testing, gene panel, etc.)
- Parent(s) and/or the index case subject to a court-ordered protective measure
- The index case and his or her parents have a condition that, in the investigator's opinion, would contraindicate the subject's participation in the study
- Presence of an intellectual developmental disorder confirmed by a neuropsychological test or strongly suspected clinically in the index case and/or their parents
- Index case with a clear syndromic diagnosis
- Index case with a psychiatric disorder already covered by a pre-indication under PFMG2025.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
The index case and his two parents
Index cases with one or more psychiatric disorders
|
Collection of an EDTA blood sample from the index case and his or her two biological parents
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Identification of at least one likely pathogenic or pathogenic variant (ACMG classification class 4/5) responsible for a condition that explains the patient(s psychiatric symptoms.
時間枠：8 months
|
8 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。